Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DAP000559

Drug Information
NameGalantamine
SynonymsASUTZQLVASHGKV-JDFRZJQESA-; BSPBio_000436; (-)-Galanthamine; Reminyl (TN); Galantamine [USAN:INN]; 4-27-00-02184 (Beilstein Handbook Reference); BRD-K49481516-004-03-5; Prestwick2_000588; Prestwick3_000588; 6H-Benzofuro(3a,3,2-ef)(2)benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-; AC1L1TIM; CHEMBL659; Spectrum3_001738; BRD-K49481516-004-04-3; CID9651; Galantaminum; galanthamine; SMP1_000131; AC-20240; SDCCGMLS-0066737.P001; InChI=1/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1; SPBio_002655; KBioGR_001417; Galantamin; Razadyne ER; Prestwick1_000588; BSPBio_003416; KBio2_001751; STOCK1N-46108; Galantamine (USAN/INN); (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro(3a,3,2-ef)(2)benzazepin-6-ol; KBio3_002636; D04292; 1qti; NSC 100058; Prestwick0_000588; GNT; LS-71039; C08526; Galantamine; NINDS_000590; KBio2_004319; 6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-, (4aS,6R,8aS)-; 357-70-0; 736-79-8; DivK1c_000590; Spectrum4_000839; BIDD:GT0517; BPBio1_000480; KBioSS_001751; HSDB 7361; Reminyl; Lycoremine; KBio1_000590; Galantamina; UNII-0D3Q044KCA; BRN 0093736; Galanthaminum; NCGC00024731-02; 1953-04-4; KBio2_006887; Probes2_000395; MolPort-002-521-885; 1dx6; HMS2089H03; CHEBI:42944; Jilkon; 1551-02-6; Spectrum_001271; IDI1_000590; Galantamina [INN-Spanish]; Galantaminum [INN-Latin]; Spectrum5_001673; Probes1_000055; Lycoremin
Trade NameNivalin; Razadyne; Razadyne ER; Reminyl
CompanyJanssen Pharmaceutica
IndicationAlzheimer's disease
[ICD9: 331.0   ICD10: G30]
Approved    [1]
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(
10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
InChIKeyASUTZQLVASHGKV-JDFRZJQESA-N
Canonical SMILESCN1CCC23C=CC(CC2OC4=C(C=CC(=C34)C1)OC)O    
Isomeric SMILESCN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O
Therapeutic ClassParasympathomimetics
CAS NumberCAS 357-70-0
FormulaC17H21NO3
PubChem Compound IDCID 9651.
PubChem Substance IDSID 10719.
ChEBI42944;
SuperDrug ATC IDN06DA04
SuperDrug CAS ID000357700;
TargetAcetylcholinesteraseInhibitor[2][3][4]
Ref 1Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54. To Reference
Ref 2From symptomatic to disease modifying therapy? Recent developments in the pharmacotherapy of Alzheimer's disease. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33. Epub 2009 Jun 5. To Reference
Ref 3Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease. Neuroreport. 2009 Feb 18;20(3):285-8. To Reference
Ref 4Acetylcholinesterase inhibitors enhance cognitive functions in rats following hypobaric hypoxia. Behav Brain Res. 2009 Oct 12;203(1):1-14. Epub 2009 Mar 28. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543